# IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/immotion150-a-phase-ii-trial-in-untreated-metastatic-renal-cell-carcinoma-mrcc/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Michael B. Atkins,David F. McDermott,Thomas Powles,Robert J. Motzer,Brian I. Rini,Lawrence Fong,Richard W. Joseph,Sumanta K. Pal,Mario Sznol,John D. Hainsworth,Walter M. Stadler,Thomas E. Hutson,Alain Ravaud,Sergio Bracarda,Cristina Suárez,Toni K. Choueiri,Jiaheng Qiu,Mahrukh Huseni,Christina Schiff,Bernard Escudier |
| Citations | 74 |
| DOI | 10.1200/jco.2017.35.15_suppl.4505 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2801270371 |
| Type | conference-abstract |
| Year | 2017 |

## Paper authors

- [Jiaheng Qiu](https://scholariq.org/researchers/jiaheng-qiu/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Paper topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.